Emergent BioSolutions (EBS) Change in Accured Expenses (2010 - 2026)

Emergent BioSolutions' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 37.27% year-over-year to -$20.2 million; the TTM figure through Mar 2026 stood at -$5.3 million (down 139.55% YoY), while the FY2025 annual figure was -$17.3 million, down 240.65% from the prior year.
• Change in Accured Expenses was -$20.2 million for Q1 2026 at Emergent BioSolutions, down from $9.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $37.1 million in Q2 2024 to a low of -$61.0 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged -$8.7 million across 5 years, with a median of -$700000.0 in 2025.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses tumbled 503.97% in 2022, then soared 4022.22% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$61.0 million in 2022, then grew by 10.0% to -$54.9 million in 2023, then jumped by 140.44% to $22.2 million in 2024, then plunged by 56.31% to $9.7 million in 2025, then tumbled by 308.25% to -$20.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$20.2 million (Q1 2026), $9.7 million (Q4 2025), and -$700000.0 (Q3 2025), per Business Quant data.